Introduction
============

Bacillus Calmette-Guerin (BCG), an attenuated strain of *Mycobacterium bovis,* is used for vaccination of infants. The onset of disseminated BCG infection, such as disseminated lymphadenitis or osteomyelitis, has rarely been reported ([@B1]). BCG has also been used to prevent superficial bladder cancer recurrence ([@B2]) and its serious complications such as bladder tuberculosis, sepsis, hepatitis, encephalomyelitis, cystitis, pyelonephritis, nephritis, prostatitis, epididymis, aneurysms and spondylitis are rare ([@B3]). However, many cases may not have been reported because of the lack of a proper microbiological examination. To our knowledge, only 13 cases of tuberculous spondylitis as complications have been reported to date.

We herein report a case of *M. bovis* tuberculosis spondylitis that developed three months after intravesical BCG therapy based on hospital records. We present this case study because of its rare occurrence and the severe consequences of a delayed diagnosis. An ethics statement and informed consent were obtained.

Case Report
===========

A 74-year-old man presented with a 7-month history of lower left back pain following an operation. A year and a half before admission, the patient had been diagnosed with bladder cancer and received intravesical BCG therapy. While receiving therapy, he developed a fever of 40℃ that ameliorated after a few days. He also had a history of hypertension.

At the time of hospital admission for lower back pain, the patient\'s vital signs were stable. He experienced buttock pain when getting up, but walking was possible. A lower limb extension elevation test was negative. Deep tendon reflexes were normal, and there was no motor weakness or paresthesia.

Initial routine laboratory examinations showed microcytic anemia, a normal white blood cell count, an erythrocyte sedimentation rate of 29 mm/first hour, and a C-reactive protein level of 0.68 mg/dL. No immunodeficiency was observed, and the QuantiFERON-TB (QFT) (Cellestis, Chadstone, Australia) test result was negative. Plain radiographs showed T1 and L2 compression fractures ([Fig. 1](#g001){ref-type="fig"}). Magnetic resonance imaging (MRI) of the pine showed a high signal intensity in the L1 and L2 vertebral body, diagnosed as a cystic lesion at the T2 to L2 level epidural and bilateral intestinal psoas muscle ([Fig. 2](#g002){ref-type="fig"}).

![Plain radiograph showing T1 and L2 compression fractures.](1349-7235-59-0733-g001){#g001}

![Magnetic resonance imaging (MRI) of the spine showing high signal intensity in the L1 and L2 vertebral body, diagnosed as a cystic lesion in the Th2 to L2 level epidural and bilateral intestinal psoas muscle.](1349-7235-59-0733-g002){#g002}

Because purulent spondylitis and iliopsoas abscess were suspected based on the imaging findings, on the same day, a computed tomography (CT)-guided needle biopsy was performed under suspicion of an infection. Bacterial cultures of the biopsy specimens revealed infection with *M. tuberculosis* group, and antimicrobial susceptibility testing showed that only pyrazinamide was resistant. Because the QFT test result was negative and there was a history of BCG administration, purulent spondylitis caused by BCG was suspected, and an anti-tuberculosis treatment of isoniazid (300 mg/day), rifampicin (450 mg/day), and ethambutol (750 mg/day) was started. At a later date, *M. bovis* was identified using multiplex polymerase chain reaction ([@B4]) ([Fig. 3](#g003){ref-type="fig"}). Two months later, the patient\'s lower left back pain had resolved completely. One year after antituberculous treatment had been started, the patient was pain-free with no functional limitations or recurrent infection.

![*Mycobacterium bovis* was identified using a multiplex polymerase chain reaction assay.](1349-7235-59-0733-g003){#g003}

Discussion
==========

Intravesical BCG therapy for the treatment of superficial bladder cancer has a low risk of extravesical complications, which are rare ([@B5]), but adverse effects such as cystitis, a fever, hematuria, prostatitis, arthralgias, and reactive arthritis are relatively common. The first study to mention tuberculous spondylitis caused by intravesical BCG therapy was reported in 1992, but only 13 cases related to intravesical BCG therapy for bladder cancer have been reported since ([@B6]-[@B17]) ([Table](#t001){ref-type="table"}). In most cases, BCG spondylitis develops several months after intravesical BCG therapy, while some cases may develop several years later, but the cause is unknown ([@B13]). It is important to confirm the history of intravesical BCG for the differential diagnosis because *M. bovis* BCG may spread hematogenously to distant sites over the course of months or years and develop into *M. bovis* BCG infection.

###### 

Only 14 Cases of Tuberculous Spondylitis Caused by Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Bladder Cancer have been Reported since 1992.

  Reference   Patient age (year)   Dose                                                                   Site of infection               Time of onset after BCG therapy   History of tuberculosis or vaccination with BCG   Quanti-FERON-TB test results   Tuberculin test   Diagnosis and culture                                         Antimicrobial therapy and outcome
  ----------- -------------------- ---------------------------------------------------------------------- ------------------------------- --------------------------------- ------------------------------------------------- ------------------------------ ----------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  \(5\)       67                   40 mg/month for 12 months                                              Vertebral or psoas abscess      6 months                          No history                                        Unknown                        Unknown           Positive tissue biopsy cultures for *M.*^1^*bovis*            Isoniazid and rifampin; discharged after 2 months
  \(6\)       90                   Weekly instillation for 6 weeks                                        Vertebral                       1 months                          No history                                        Unknown                        Anergy            Open surgical biopsy; culture positive for *M. bovis*         Isoniazid and rifampin, ethambutol; not specified
  \(7\)       81                   One instillation per week for 6 weeks, then 1 per month for 2 months   Vertebral                       7 months                          No history                                        Unknown                        Negative          Open surgical biopsy; blood culture positive for *M. bovis*   Isoniazid and rifampin for 1 year; alive 1 year later
  \(9\)       77                   2 cycles (6 treatments/cycle)                                          Vertebral                       2 weeks                           Unknown                                           Unknown                        Unknown           Positive tissue biopsy cultures for *M. bovis*                Isoniazid, rifampin and ethambutol for 6 months, then isoniazid and rifampin for 6 months; alive 1 year later
  \(18\)      66                   60 mg/week for 12 weeks                                                Hip arthroplasty                1.7 years                         Unknown                                           Unknown                        Anergy            Positive surgical culture for *M. bovis*                      Isoniazid and rifampin; died of lung cancer 3 years later
  \(10\)      79                   One instillation per week for 8 weeks                                  Vertebral                       2.5 years                         Unknown                                           Unknown                        Unknown           Surgical tissue cultures positive for *M. bovis*              Isoniazid and rifampin for 12 months; alive 1 year later
  \(11\)      76                   6 weekly cycles                                                        Vertebral                       7 years                           No history                                        Unknown                        Negative          Positive tissue biopsy cultures for *M. bovis*                Isoniazid, rifampin and ethambutol for 12 months; not specified
  \(12\)      72                   Weekly instillation for 6 weeks                                        Vertebral                       12 years                          Unknown                                           Unknown                        Anergy            Open surgical biopsy; culture positive for *M. bovis*         Isoniazid, rifampin and ethambutol for 12 months; alive 1.5 years later
  \(13\)      58                   Unknown                                                                Vertebral and aortic graft      3 years                           Unknown                                           Unknown                        Negative          Positive tissue biopsy cultures for *M. bovis*                Isoniazid, rifampin for 12 months; alive 1.5 years later
  \(14\)      94                   Unknown                                                                Vertebral                       5 months                          Unknown                                           Unknown                        Unknown           Positive tissue biopsy cultures for *M. bovis*                Unknown
  \(15\)      70                   12.5 mg every week for 6 weeks                                         Vertebral and aortic aneurysm   1 month                           Unknown                                           Unknown                        Unknown           Open surgical biopsy; culture positive for *M. bovis*         Isoniazid, rifampin and ethambutol for 12 months; alive 1.5 years later
  \(16\)      82                   8 cycles                                                               Vertebral                       16 months                         Unknown                                           Negative                       Unknown           Open surgical biopsy; culture positive for *M. bovis*         Isoniazid, rifampin and ethambutol for 6 months; alive 1 year later
  \(17\)      64                   5 instillations                                                        Vertebral                       6 months                          Unknown                                           Unknown                        Unknown           Positive tissue biopsy cultures for *M. bovis*                Isoniazid, rifampin, ethambutol, cycloserine and moxifloxacin for 12 months; not specified
  This case   74                   Unknown                                                                Vertebral                       1.5 years                         No history                                        Negative                       Unknown           Positive tissue biopsy cultures for *M. bovis*                Isoniazid, rifampin and ethambutol for 12 months; alive 1 year later

^1^M.: Mycobacterium

Several risk factors are associated with an incidence of disseminated BCG infection, such as bladder epithelium injury, urethral injury during BCG installation, deep bladder tumor resection, pelvic radiation, severe cystitis, a bladder biopsy, and prostate resection ([@B5],[@B7],[@B18]). However, since these risk factors were not observed in the present case, it was necessary to differentiate tuberculous spondylitis, despite the absence of any risk factors.

The QFT test is useful for the differential diagnosis of *M. bovis* BCG and *M. tuberculosis* when there is no history of tuberculosis. Specific antigens used in QFT testing are present in non-BCG *M. tuberculosis* complex but are not present in *M. bovis* BCG; therefore, they are useful for differentiation. When the QFT test is negative and the histological examination reveals the presence of pathogenic bacteria from the Mycobacteriaceae family, clinicians should strongly suspect *M. bovis* BCG infection. Of course, this method is not useful if the patient already has a history of infection with *M. tuberculosis* and is already positive for QFT. The existence of anti-interferon γ autoantibody in the present case was very unlikely because the successful evaluation by QFT suggested that IFNγ in the positive control had been normally measured.

During differentiation, we also performed a multiplex polymerase chain reaction (PCR) assay using a dual-priming oligonucleotide system targeting the RD1 gene for simultaneous identification of the *M. tuberculosis* complex and *M. bovis* BCG ([@B4]). In our case, the QFT test was negative, and multiplex PCR revealed that the *M. tuberculosis* complex was *M. bovis* BCG.

All strains of *M. bovis* are resistant to pyrazinamide, but *M. tuberculosis* is not. Therefore, isoniazid and rifampicin with ethambutol should be used as first-line agents to treat *M. bovis* infections ([@B11]). There is no clear evidence concerning the ideal duration of treatment for BCG spondylitis. For general treatment of tuberculosis when pyrazinamide cannot be used, RFP, INH and EB are continued for two months, and RFP and INH are continued for seven months. This case was resistant to pyrazinamide, and after confirming clinical symptoms and improvement in CRP, RFP, INH and EB were continued for three months and RFP and INH for four and a half months. If tuberculous spondylitis is resistant to antibiotics, or if neurological symptoms or instability of the spinal column appears, surgery should also be considered ([@B19]).

In conclusion, this case highlighted two important issues. First, BCG spondylitis can occur several years after intravesical BCG. Thus, it is necessary to test for tuberculous spondylitis if lower back pain appears in a patient who has undergone BCG therapy. Second, the QFT test is useful for the differential diagnosis of *M. bovis* BCG infection.
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